Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Story Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostAuthored by Chris Markoch. Article Published: 2/5/2026. 
At a Glance - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer delivered adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 drug candidate. After signing more than 220 Executive Orders… more than any president in American history… Donald Trump is preparing for one final move.
On February 24th — I have every reason to believe he will sign his Final Executive Order.
When I say that it's his FINAL executive order… Click here or below for this unbelievable story… PFE stock closed up 4% on Feb. 4 as analysts and investors digested the report. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and its accelerating use of artificial intelligence across R&D. That starts with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. Data shows the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035, a compound annual growth rate (CAGR) of about 9.7%. That growth explains why billions of dollars are pouring into the industry as companies try to carve out market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of 28 weeks. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom pointed to the positive clinical trial results as the reason for the stock's gain. That may be true, but it could be a short-lived rally. While Pfizer's obesity drugs show promise, it will take time for that potential to meaningfully impact the company's financials. The GLP-1 trade is also getting more competitive — as Eli Lilly & Co. (NYSE: LLY) demonstrated with a strong earnings report — and Lilly isn't planning to cede its leadership position in obesity anytime soon. There are, however, additional reasons to be bullish on PFE, particularly its oncology portfolio. Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026, projected to climb to $648.08 billion by 2035, a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its development portfolio — a large number of opportunities to capture market share. The portfolio was strengthened significantly after its acquisition of Seagen in 2023. Today, Pfizer's pipeline includes late-stage candidates such as vepdegestrant, a next-gen targeted protein degrader (PROTAC), and atirmociclib, a selective CDK4 inhibitor, both being studied for ER+/HER2- metastatic breast cancer. Other late-stage candidates include: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., BE6A LUNG-01) against metastatic non-small cell lung cancer, leveraging Seagen-acquired ADC expertise.
- Sasanlimab, targeting bladder cancer, while the bispecific PD-1xVEGF agent (PF-4404) is being studied in combination with Padcev for urothelial cancer — positioning these agents as potential blockbusters amid oncology growth.
Pfizer could bring multiple drugs to market over the next five to 10 years. That outlook is enhanced by the company's commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships like Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics. These tools — including OncoScout — have sped target identification by at least 50%. Internally, platforms such as "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) optimize discovery and manufacturing workflows. These efforts helped accelerate the development of Paxlovid and underpin 2026 catalysts in oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 through efficiency gains. Industry-wide, AI is projected to boost productivity by 35% to 45% by improving preclinical decision-making and trial design, making it a core competitive advantage rather than optional hype. Pfizer has positioned itself near the forefront of AI adoption in drug discovery, which should benefit investors over the medium and long term.
| 
